JP drafts for public comments, March 1 - May 31, 2018
New general tests
- 2.66 Elemental Impurities - Procedures (001-1803eng.pdf)
New monographs
- Bromfenac Sodium Hydrate (002-1803eng.pdf)
- Bromfenac Sodium Ophthalmic Solution (003-1803eng.pdf)
- Cefixime Fine Granules (004-1803eng.pdf)
- Doripenem Hydrate (005-1803eng.pdf)
- Doripenem for Injection (006-1803eng.pdf)
- Felodipine (007-1803eng.pdf)
- Felodipine Tablets (008-1803eng.pdf)
- Peginterferon Alfa-2b (Genetical Recombination) (009-1803eng.pdf)
- Irinotecan Hydrochloride Hydrate (010-1803eng.pdf)
- Nortriptyline Hydrochloride Tablets (011-1803eng.pdf)
- Polaprezinc (012-1803eng.pdf)
- Polaprezinc Granules (013-1803eng.pdf)
- Sodium Valproate Extended-release Tablets A (014-1803eng.pdf)
- Sodium Valproate Extended-release Tablets B (015-1803eng.pdf)
- Telmisartan and Hydrochlorothiazide Tablets (016-1803eng.pdf)
- Valsartan and Hydrochlorothiazide Tablets (017-1803eng.pdf)
New monographs (Crude drug)
- Goshuyuto Extract (018-1803eng.pdf)
Ultraviolet-visible reference spectra
- Bromfenac Sodium Hydrate (019-1803eng.pdf)
- Doripenem Hydrate (020-1803eng.pdf)
- Felodipine (021-1803eng.pdf)
- Irinotecan Hydrochloride Hydrate (022-1803eng.pdf)
Infrared reference spectra
- Bromfenac Sodium Hydrate (023-1803eng.pdf)
- Doripenem Hydrate (024-1803eng.pdf)
- Felodipine (025-1803eng.pdf)
- Irinotecan Hydrochloride Hydrate (026-1803eng.pdf)
- Polaprezinc (027-1803eng.pdf)
To send the comment on these drafts, the guidance is as follows:
- Download the form for comments in Word format
- Fill in the form
- Prepare and attach the supportive data that scientifically validate the comment when appropriate
- Send it to the email address: JPdraft1803eng●pmda.go.jp
Note: For the purpose of security, this email address is partly incorrect. Please replace ● with @ when sending an email.
Related Information
Note: The information provided with the comment may be released to the public whenever necessary (except the individual name, organization, address, telephone & fax numbers and e-mail address or the attached supportive data).